glutamic acid has been researched along with oxidopamine in 154 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (5.19) | 18.7374 |
| 1990's | 23 (14.94) | 18.2507 |
| 2000's | 61 (39.61) | 29.6817 |
| 2010's | 52 (33.77) | 24.3611 |
| 2020's | 10 (6.49) | 2.80 |
| Authors | Studies |
|---|---|
| Boulu, RG; Buisson, A; Callebert, J; Mathieu, E; Plotkine, M | 1 |
| Hayashi, J; Hirata, M; Itoh, H; Kawasaki, S; Nakagawa, M; Nakata, T; Oguro, M; Sasaki, S; Takeda, K; Tanaka, M | 1 |
| Harsing, LG; Vizi, ES | 1 |
| Alberch, J; Arenas, E; Marsal, J | 1 |
| Herrera-Marschitz, M; Kehr, J; Reid, MS; Ungerstedt, U | 1 |
| Baisden, RH; Drye, RG; Whittington, DL; Woodruff, ML | 1 |
| Lindefors, N; Ungerstedt, U | 1 |
| Dusticier, N; Kerkerian, L; Nieoullon, A | 1 |
| Felsten, G; Sved, AF | 1 |
| Kerkerian, L; Nieoullon, A | 1 |
| Busto, R; Dietrich, WD; Ginsberg, MD; Globus, MY; Martinez, E; Valdes, I | 1 |
| Loewy, AD; Neil, JJ | 1 |
| Acheson, AL; Chiodo, LA; Stricker, EM; Zigmond, MJ | 1 |
| Loewy, AD; Neil, JJ; Sawyer, WB; Stanek, KA | 1 |
| McBean, GJ; Roberts, PJ; Sharif, NA; Thomas, EM | 1 |
| Bickford, P; Friedemann, M; Gerhardt, GA; Hoffer, BJ; Luthman, J; Olson, L | 1 |
| Daszuta, A; Forni, C; Moukhles, H; Nieoullon, A | 1 |
| Brodin, E; Goiny, M; Herrera-Marschitz, M; Hökfelt, T; Meana, JJ; Morino, P; Silveira, R; Ungerstedt, U; You, ZB | 1 |
| Kondoh, T; Low, WC | 1 |
| Greenamyre, JT | 1 |
| Pierce, RC; Rebec, GV | 1 |
| Lopes da Silva, FH; Manshanden, I; Mulder, AB; van Ree, JM; Vos, PE; Wolterink, G | 1 |
| Altar, CA; Boylan, CB; Fritsche, M; Hyman, C; Jackson, C; Jones, BE; Juhasz, M; Lindsay, RM; Wiegand, SJ | 1 |
| Godukhin, O; Goiny, M; Herrera-Marschitz, M; Hökfelt, T; Kehr, J; Nylander, I; Pettersson, E; Shou, HZ; Terenius, L; Ungerstedt, U; You, ZB | 1 |
| Furtado, JC; Garside, S; Mazurek, MF | 1 |
| Biggs, CS; Fowler, LJ; Starr, MS; Whitton, PS | 1 |
| Allen, C; Buckman, JF; Donohue, MK; Emre, N; Meshul, CK; Nakamura, CM | 1 |
| Herrera-Marschitz, M; Hökfelt, T; Koistinaho, J; Rodríguez-Puertas, R | 1 |
| Caruncho, HJ; Labandeira-Garcia, JL; Liste, I; Rodriguez-Pallares, J | 1 |
| Abarca, J; Bustos, G | 1 |
| Clemens, JA; Du, Y; Johnstone, EM; Little, SP; Liu, X; Panetta, JA; Paul, SM; Stephenson, DT; Yin, T | 1 |
| Berger, SP; Fox, L; Ho, LB; Reid, MS | 1 |
| Allen, C; Meshul, CK | 1 |
| Beani, L; Bianchi, C; Fuxe, K; Marti, M; Morari, M; Sbrenna, S | 1 |
| Fisone, G; Goiny, M; Goldstein, M; Haycock, J; Herrera-Marschitz, M; Hökfelt, T; Lindgren, N; Lindskog, M; Xu, ZQ | 1 |
| Andbjer, B; Fuxe, K; Kehr, J; Strömberg, I | 1 |
| Badiani, A; Browman, KE; Fraioli, S; Oates, MM; Ostrander, MM; Robinson, TE; Wolf, ME; Xue, CJ | 1 |
| Dunnett, SB; Everitt, BJ; Meldrum, A | 1 |
| Akaike, A; Ibi, M; Kaneko, S; Katsuki, H; Kume, T; Nakanishi, M; Sawada, H; Shimohama, S | 1 |
| Blandini, F; Fancellu, R; Greenamyre, JT; Nappi, G | 1 |
| Benabid, AL; Benazzouz, A; Bouali-Benazzouz, R; Gao, D; Ni, Z | 1 |
| Krentz, L; Meshul, CK; Moore, C; Robinson, S | 1 |
| Chen, L; Li, S; Liu, Z; Tian, Z; Wang, Y | 1 |
| Ebinger, G; Jonkers, N; Michotte, Y; Sarre, S | 1 |
| Liu, XJ; Sawynok, J; White, TD | 1 |
| Kamel, D; Kay, TS; Krentz, L; Meshul, CK; Moore, C | 1 |
| Bari, M; Battista, N; Bernardi, G; Calabresi, P; Centonze, D; Finazzi-Agrò, A; Gubellini, P; Maccarrone, M; Picconi, B | 2 |
| Inoue, O; Kagawa, S; Nakano, T; Nishimura, T | 1 |
| During, MJ; Fitzsimons, HL; Kaplitt, MG; Liu, Y; Luo, J; Oshinsky, ML; Zuzga, DS | 1 |
| Beani, L; Bianchi, C; Marti, M; Mela, F; Morari, M | 1 |
| Corsi, C; Gianfriddo, M; Melani, A; Morelli, M; Pedata, F; Pinna, A | 1 |
| Ding, JH; Hu, G; Li, H | 1 |
| Bianchi, L; Bolam, JP; Della Corte, L; Galeffi, F | 1 |
| Frederickson, J; Meshul, CK; Moore, C; Touchon, JC | 1 |
| Kase, H; Ochi, M; Shiozaki, S | 2 |
| Ding, JH; Gu, B; He, HR; Hu, G; Meng, CH; Yang, YL | 1 |
| Alonso, TJ; Castro Fuentes, R; García Dopico, J; González Hernández, T; Perdomo Díaz, J; Rodríguez Díaz, M | 1 |
| Bernardi, G; Calabresi, P; Centonze, D; Picconi, B; Rossi, S | 1 |
| Bielicki, G; Chassain, C; Donnat, JP; Durif, F; Eschalier, A; Renou, JP | 1 |
| Johnson, SW; Shen, KZ | 1 |
| Bianchi, C; Della Corte, L; Fantin, M; Manzalini, M; Marti, M; Morari, M | 1 |
| Mignon, LJ; Wolf, WA | 1 |
| Baunez, C; Bernardi, G; Calabresi, P; Centonze, D; Gubellini, P; Picconi, B; Pisani, A; Rossi, S | 1 |
| Lapish, CC; Lavin, A; Nogueira, L; Phillips, PE; Seamans, JK; Wightman, RM | 1 |
| Carcenac, C; Poupard, A; Savasta, M; Windels, F | 1 |
| Kress, GJ; Reynolds, IJ | 1 |
| Baker, D; Cabranes, A; de Lago, E; Fernández-Ruiz, J; López-Rodríguez, M; Ortega-Gutiérrez, S; Pryce, G; Ramos, JA | 1 |
| Ding, JH; Hu, G; Hu, LF; Liu, X; Yang, J; Zhou, F | 1 |
| de Miguel, R; Fernández-Ruiz, J; García-Arencibia, M; González, S; Ramos, JA; Scorticati, C | 1 |
| Namba, H; Nawa, H; Sudou, K; Zheng, Y | 1 |
| Mignon, L; Wolf, WA | 1 |
| Marti, M; Morari, M; Trapella, C; Viaro, R | 1 |
| Croucher, MJ; Datla, KP; Dexter, DT; Vernon, AC; Zbarsky, V | 1 |
| Ampe, B; D'Haens, J; Ebinger, G; Massie, A; Michotte, Y; Sarre, S | 1 |
| Lee, HH; Lin, CT; Yang, LL | 1 |
| Fernández-Ruiz, J; Ferraro, L; García-Arencibia, M; Tanganelli, S | 1 |
| Kitta, T; Matsumoto, M; Mitsui, T; Nonomura, K; Tanaka, H; Yoshioka, M | 1 |
| Sengpiel, F; Vorobyov, V | 1 |
| Bérubé-Carrière, N; Dal Bo, G; Descarries, L; Leo, D; Lévesque, D; Mendez, JA; Riad, M; Trudeau, LE | 1 |
| Ardestani, MS; Moghaddamt, HF; Navidpour, L; Rahmim, A; Saffari, M; Shafiee, A | 1 |
| Marti, M; Morari, M; Trapella, C | 1 |
| Mabrouk, OS; Marti, M; Morari, M; Volta, M | 1 |
| Kostrzewa, RM | 1 |
| Shimohama, S | 1 |
| Abarca, J; Bustos, G; Bustos, V; Campusano, J; Moya, C; Noriega, V; Riquelme, E | 1 |
| Koch, RJ; Meshul, CK; Moore, C; Sweeney, JE; Walker, RH | 1 |
| Kajiwara, R; Takashima, I; Watanabe, Y | 1 |
| Acher, F; Barabino, E; Beurrier, C; Cuomo, D; Goudet, C; Gubellini, P; Kerkerian-Le Goff, L; Madeo, G; Martella, G; Melon, C; Oueslati, N; Pin, JP; Pisani, A; Platania, P; Selvam, C; Vita, D | 1 |
| Mabrouk, OS; Marti, M; Morari, M; Salvadori, S | 1 |
| Bérubé-Carrière, N; Dal Bo, G; Descarries, L; Lévesque, D; Riad, M; Trudeau, LE | 1 |
| Deutch, AY; Garcia, BG; Neely, MD | 1 |
| Jeong, BS; Nam, TG; Niki, E; Omata, Y; Porter, NA; Saito, Y; Serwa, R; Yoshida, Y | 1 |
| Bertrand, A; Dentresangle, C; Detraz, I; Dzahini, K; Le Cavorsin, M; Leviel, V; Savasta, M | 1 |
| Davies, G; Haack, AK; Koch, RJ; Meshul, CK; Moore, C; Walker, RH | 1 |
| Black, YD; Brownell, AL; Kachroo, A; Pellegrino, D; Schwarzschild, MA; Xiao, D | 1 |
| Bannai, S; Beck, H; Conrad, M; De Bundel, D; Fernando, R; Kim, SW; Kobayashi, S; Massie, A; Michotte, Y; Plesnila, N; Sato, H; Schallier, A; Smolders, I; Vermoesen, K | 1 |
| Kuruvilla, KP; Malat, A; Nandhu, MS; Paul, J; Paulose, CS; Romeo, C | 1 |
| Fernández-Ruiz, J; García, C; García-Arencibia, M; Palomo-Garo, C; Pertwee, R; Ramos, J | 1 |
| Bishop, C; Button, T; Dupre, KB; Eskow Jaunarajs, KL; Ostock, CY; Savage, LM; Wolf, W | 1 |
| Chandler, LJ; Gorelova, N; Mulholland, PJ; Seamans, JK | 1 |
| Deng, C; Huang, XF; Wang, Q; Wu, A; Xiong, Z; Xu, Y; Yan, J; Yang, Y; Yang, YG; Yenari, MA; Ying, W; Zhang, L; Zhu, C | 1 |
| Dziubina, A; Gołembiowska, K | 1 |
| Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N | 1 |
| Hall, SD; Magill, PJ; Stanford, IM; Woodhall, GL; Yamawaki, N | 1 |
| Antonelli, T; Beggiato, S; Ferraro, L; Fuxe, K; O'Connor, WT; Tanganelli, S; Tomasini, MC | 1 |
| Bai, GH; Gao, HC; Li, XK; Lin, L; Song, CY; Xiang, Y; Yan, ZH; Ye, FQ; Zhu, H | 1 |
| Bezard, E; Brambilla, R; Calabresi, P; Fasano, S; Guerrini, R; Li, Q; Marti, M; Morari, M; Morella, I; Rodi, D; Simonato, M; Tozzi, A | 1 |
| Alonso-Gil, S; Conde, S; Gil, C; Martínez, A; Morales-García, JA; Palomo, V; Pérez, C; Pérez, DI; Pérez-Castillo, A; Santos, A; Susín, C | 1 |
| Auberson, YP; Budri, M; Calcagno, M; Dekundy, A; Mabrouk, OS; Mela, F; Morari, M; Parsons, CG; Viaro, R | 1 |
| Fang, F; Fang, K; Hou, Z; Lei, H; Lin, X; Liu, M; Liu, S; Meng, H; Sun, B; Zhang, Z | 1 |
| Antipov, PI; Antipova, TA; Gudasheva, TA; Logvinov, IO; Seredenin, SB; Tarasiuk, AV | 1 |
| Arnold, JC; Bondada, V; Chotibut, T; Davis, RW; Frenchek, Z; Geddes, JW; Gurwara, S; Salvatore, MF | 1 |
| Chae, Y; Choo, HJ; Doo, AR; Kim, SN; Lee, B; Lee, H; Park, HJ; Park, JJ; Park, JY; Shim, I | 1 |
| Chergui, K; Feng, ZJ; Zhang, X | 1 |
| Du, G; Fu, Q; Huang, L; Sun, J; Yan, J | 1 |
| Antipova, TA; Gudasheva, TA; Nikolaev, SV; Seredenin, SB | 1 |
| Ampe, B; Aourz, N; Bentea, E; De Deurwaerdère, P; El Arfani, A; Massie, A; Michotte, Y; Sarre, S; Smolders, I; Van Eeckhaut, A | 1 |
| Dale, E; Doller, D; Gubellini, P; Kerkerian-Le Goff, L; Melon, C | 1 |
| Deng, X; Fang, X; Li, J; Li, S; Lu, Y; Xu, R; Zhang, J; Zhou, Y | 1 |
| Antipova, TA; Bakulin, DA; Kurkin, DV; Logvinov, IO; Tiurenkov, IN; Volotova, EV | 1 |
| Lin, L; Liu, T; Meng, T; Yuan, S; Zheng, Z | 1 |
| Albrieux, M; Boisseau, S; Bosson, A; Buisson, A; Savasta, M | 1 |
| Albertini, G; Bentea, E; Demuyser, T; El Arfani, A; Massie, A; Smolders, I; Van Eeckhaut, A | 1 |
| Arcuri, L; Brugnoli, A; Mercatelli, D; Morari, M; Paolone, G | 1 |
| Alvarsson, A; Kadkhodaei, B; Millan, MJ; Perlmann, T; Schintu, N; Stan, TL; Svenningsson, P; Zhang, X | 1 |
| Cai, X; Chen, D; Gao, H; Jin, K; Liao, J; Liu, X; Ma, L; Tang, B; Wang, Q; Wei, X; Xia, Y; Xu, Y; Zhang, Z; Zou, J | 1 |
| Chassain, C; Couraud, S; Durif, F; Gubellini, P; Kerkerian-Le Goff, L; Melon, C; Salin, P; Vitale, F | 1 |
| McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Jiang, Y; Liu, B; Lu, L; Shi, X; Sun, X | 1 |
| Guzman, DM; Naughton, SX; Parikh, V; Yegla, B | 1 |
| Asensio, MJ; García-Sanz, P; Herranz, AS; Moratalla, R; Solís, O | 1 |
| Filiz, Z; Korkmaz, OT; Kuş, G; Şener, E; Tunçel, N; Ulupinar, E; Yelkenli, İH | 1 |
| Deng, JH; Gong, XL; Jia, J; Jia, YJ; Sun, ZL; Wang, XM; Yang, J; Yu, Y; Zhang, WZ | 1 |
| Blobaum, AL; Bubser, M; Conn, PJ; Daniels, JS; Engers, DW; Hopkins, CR; Javitch, JA; Jones, CK; Lin, X; Lindsley, CW; Loch, MT; Niswender, CM; Rodriguez, AL; Thompson Gray, A | 1 |
| Antipova, TA; Gudasheva, TA; Koliasnikova, KN; Seredenin, SB | 1 |
| Bishop, C; Conti, MM; George, JA; Goldenberg, AA; Lindenbach, D; Melikhov-Sosin, M; Nuss, EE; Ostock, CY | 1 |
| An, W; Bai, XX; Bao, LH; Gu, L; Wang, XM; Xi, SS; Yang, HM; Zhang, H | 1 |
| Hu, S; Li, Q; Li, Y; Liu, X; Wang, D; Zhang, J | 1 |
| Akiyama, JI; Aono, H; Choudhury, ME; Fujita, K; Higaki, H; Kigami, Y; Kubo, M; Miyanishi, K; Nishikawa, N; Nomoto, M; Takahashi, H; Tanaka, J; Yano, H | 1 |
| Du, CX; Guo, Y; Li, LB; Liu, J; Sun, YN; Wang, Y; Yao, L | 1 |
| Hou, L; Lin, X; Liu, X; Qiao, D; Shi, K | 1 |
| Chen, C; Dai, Y; Ding, L; Li, H; Lu, Z; Mo, M; Wei, L; Wu, H; Xu, P; Zou, J | 1 |
| Mannoury-la-Cour, C; Mantas, I; Millan, MJ; Svenningsson, P; Yang, Y; Zhang, X | 1 |
| Brugnoli, A; Caccia, C; Keywood, C; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Vailati, S | 1 |
| Bastioli, G; Caccia, C; Calabresi, P; Cardinale, A; Ghiglieri, V; Keywood, C; Mazzocchetti, P; Melloni, E; Mosci, P; Padoani, G; Picconi, B; Sciaccaluga, M; Tozzi, A; Vailati, S | 1 |
| Cuboni, E; Di Giovanni, G; Fedele, E; Galati, S; Grandi, LC; Kaelin-Lang, A; Orban, G; Salvadè, A; Song, W; Stefani, A | 1 |
| Brugnoli, A; Morari, M; Pisanò, CA | 1 |
| Gao, S; Guo, Y; Li, R; Li, W; Liu, J; Lyu, S; Tang, G; Yang, J; Zhang, L | 1 |
| Boutin, J; Fougère, M; Neszvecsko, K; Ryczko, D; Sarret, P; van der Zouwen, CI | 1 |
| Jia, J; Li, M; Su, W; Wang, K; Wang, X | 1 |
| Aguirre-Pérez, A; Alfaro-Rodriguez, A; Arias-Montaño, JA; Avila-Luna, A; Bueno-Nava, A; Gálvez-Rosas, A; Hidalgo-Bravo, A; Ríos, C | 1 |
| Chernov, MM; Leiter, JC; Swan, CB | 1 |
3 review(s) available for glutamic acid and oxidopamine
| Article | Year |
|---|---|
Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Agents; Drug Evaluation, Preclinical; Drug Synergism; Drug Tolerance; Excitatory Amino Acid Antagonists; Glutamates; Glutamic Acid; Haplorhini; Humans; Mice; MPTP Poisoning; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Quinoxalines; Rats; Receptors, Dopamine; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission | 1993 |
Evolution of neurotoxins: from research modalities to clinical realities.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Benzylamines; Botulinum Toxins, Type A; Dihydroxyphenylalanine; Dihydroxytryptamines; Glutamic Acid; Humans; Models, Animal; Nerve Growth Factor; Neurosciences; Neurotoxins; Oxidopamine; Terminology as Topic | 2009 |
Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Amyloid beta-Peptides; Animals; Drug Synergism; Galantamine; Glutamic Acid; Motor Neurons; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinson Disease, Secondary; Phosphatidylinositol 3-Kinases; Rats; Receptors, Nicotinic; Rotenone; Signal Transduction; Spinal Cord | 2009 |
151 other study(ies) available for glutamic acid and oxidopamine
| Article | Year |
|---|---|
Striatal protection induced by lesioning the substantia nigra of rats subjected to focal ischemia.
Topics: Animals; Aspartic Acid; Brain Ischemia; Cerebral Infarction; Corpus Striatum; Dopamine; Extracellular Space; Glutamates; Glutamic Acid; Male; Oxidopamine; Rats; Rats, Inbred Strains; Substantia Nigra | 1992 |
Enhanced norepinephrine release in hypothalamus from locus coeruleus in SHR.
Topics: Animals; Blood Pressure; Glutamates; Glutamic Acid; Hydroxydopamines; Hypertension; Hypothalamus; Locus Coeruleus; Microinjections; Norepinephrine; Oxidopamine; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 1991 |
Alpha 2-adrenoceptors are not involved in the regulation of striatal glutamate release: comparison to dopaminergic inhibition.
Topics: 4-Butyrolactone; Animals; Apomorphine; Berberine; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Drug Interactions; Glutamates; Glutamic Acid; Haloperidol; Hydrazines; Hydroxydopamines; Male; Oxidopamine; Potassium Chloride; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Secretory Rate; Synaptic Transmission; Yohimbine | 1991 |
Dopaminergic system mediates only delta-opiate inhibition of endogenous acetylcholine release evoked by glutamate from rat striatal slices.
Topics: Acetylcholine; Animals; Benzazepines; Corpus Striatum; Dopamine; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Enkephalin, Leucine-2-Alanine; Enkephalins; Glutamates; Glutamic Acid; Male; Morphine; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, mu; Secretory Rate | 1991 |
Striatal dopamine and glutamate release: effects of intranigral injections of substance P.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Denervation; Dopamine; Dopamine Agents; Glutamates; Glutamic Acid; Hydroxydopamines; Male; Oxidopamine; Rats; Rats, Inbred Strains; Substance P; Substantia Nigra | 1990 |
The effects of stimulation of the A5 region on blood pressure and heart rate in rabbits.
Topics: Animals; Blood Pressure; Cardiovascular Physiological Phenomena; Electric Stimulation; Glutamates; Glutamic Acid; Heart Rate; Hydroxydopamines; Male; Medulla Oblongata; Oxidopamine; Pons; Rabbits | 1990 |
Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons.
Topics: Animals; Corpus Striatum; Dopamine; Extracellular Space; Glutamates; Glutamic Acid; Hydroxydopamines; Male; Mesencephalon; Neurotransmitter Agents; Oxidopamine; Rats; Rats, Inbred Strains | 1990 |
Modulatory effect of dopamine on high-affinity glutamate uptake in the rat striatum.
Topics: alpha-Methyltyrosine; Animals; Apomorphine; Corpus Striatum; Dopamine; Drug Synergism; Electric Stimulation; Glutamates; Glutamic Acid; Haloperidol; Hydroxydopamines; Male; Methyltyrosines; Oxidopamine; Rats; Rats, Inbred Strains; Sodium; Substantia Nigra | 1987 |
Stimulation of the locus coeruleus decreases arterial pressure.
Topics: Animals; Atropine; Blood Pressure; Carbachol; Cerebral Cortex; Electric Stimulation; Glutamates; Glutamic Acid; Heart Rate; Homocysteine; Hydroxydopamines; Locus Coeruleus; Male; Norepinephrine; Oxidopamine; Rats; Rats, Inbred Strains; Vasopressins | 1987 |
Supersensitivity of presynaptic receptors involved in the dopaminergic control of striatal high affinity glutamate uptake after 6-hydroxydopamine lesion of nigrostriatal dopaminergic neurons.
Topics: Animals; Apomorphine; Cerebral Cortex; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Electric Stimulation; Female; Glutamates; Glutamic Acid; Hydroxydopamines; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine D2; Receptors, Opioid; Substantia Nigra | 1988 |
Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and gamma-aminobutyric acid studied by intracerebral microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebrovascular Circulation; Corpus Striatum; Denervation; Dialysis; Dopamine; Energy Metabolism; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Homovanillic Acid; Hydroxydopamines; Ischemic Attack, Transient; Kinetics; Male; Oxidopamine; Rats; Rats, Inbred Strains; Substantia Nigra | 1988 |
Decreases in blood pressure in response to L-glutamate microinjections into the A5 catecholamine cell group.
Topics: Animals; Blood Pressure; Catecholamines; Electric Stimulation; Glutamates; Glutamic Acid; Guanethidine; Heart Rate; Hydroxydopamines; Mesencephalon; Microinjections; Oxidopamine; Rats; Rats, Inbred Strains; Sympathectomy, Chemical | 1982 |
Subtotal destruction of central noradrenergic projections increases the firing rate of locus coeruleus cells.
Topics: Animals; Glutamates; Glutamic Acid; Hydroxydopamines; Injections, Intraventricular; Kinetics; Locus Coeruleus; Male; Norepinephrine; Oxidopamine; Rats; Rats, Inbred Strains | 1983 |
Changes in regional blood flow and cardiac output after L-glutamate stimulation of A5 cell group.
Topics: Animals; Brain Stem; Cardiac Output; Female; Glutamates; Glutamic Acid; Guanethidine; Heart Rate; Hydroxydopamines; Oxidopamine; Rats; Rats, Inbred Strains; Regional Blood Flow; Stroke Volume; Sympathectomy, Chemical; Vascular Resistance | 1984 |
Striatal glutamatergic function: modifications following specific lesions.
Topics: Animals; Binding Sites; Cerebral Cortex; Cerebral Decortication; Corpus Striatum; Female; Glutamates; Glutamic Acid; Hydroxydopamines; Ibotenic Acid; Neural Pathways; Oxidopamine; Rats; Rats, Inbred Strains; Substantia Nigra; Synaptic Transmission | 1982 |
In vivo electrochemical measurements and electrophysiological studies of rat striatum following neonatal 6-hydroxydopamine treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Ascorbic Acid; Corpus Striatum; Dopamine; Electrochemistry; Electrophysiology; Functional Laterality; Glutamates; Glutamic Acid; Homovanillic Acid; Hydroxyindoleacetic Acid; Kinetics; Male; Neurons; Oxidopamine; Rats; Rats, Sprague-Dawley; Reference Values; Serotonin; Time Factors | 1993 |
Regulation of dopamine levels in intrastriatal grafts of fetal mesencephalic cell suspension: an in vivo voltammetric approach.
Topics: 2-Amino-5-phosphonovalerate; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Benzazepines; Brain Tissue Transplantation; Cerebral Ventricles; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dopamine D2 Receptor Antagonists; Female; Fetal Tissue Transplantation; Glutamic Acid; Injections, Intraventricular; Kinetics; Mesencephalon; N-Methylaspartate; Oxidopamine; Quisqualic Acid; Rats; Rats, Wistar; Receptors, Dopamine D1; Sulpiride; Time Factors; Transplantation, Heterotopic | 1994 |
On the origin of striatal cholecystokinin release: studies with in vivo microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Afferent Pathways; Animals; Aspartic Acid; Calcium; Cholecystokinin; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Glutamates; Glutamic Acid; Homovanillic Acid; Male; Microdialysis; Oxidopamine; Potassium; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Sincalide | 1994 |
Glutamate uptake blockade induces striatal dopamine release in 6-hydroxydopamine rats with intrastriatal grafts: evidence for host modulation of transplanted dopamine neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Diseases; Brain Tissue Transplantation; Corpus Striatum; Dopamine; Excitatory Amino Acid Antagonists; Glutamates; Glutamic Acid; Kainic Acid; Male; Mesencephalon; N-Methylaspartate; Neurons; Oxidopamine; Rats; Tyrosine 3-Monooxygenase | 1994 |
Intraneostriatal administration of glutamate antagonists increases behavioral activation and decreases neostriatal ascorbate via nondopaminergic mechanisms.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid; Dizocilpine Maleate; Glutamates; Glutamic Acid; Homocysteine; Infusions, Parenteral; Male; Motor Activity; Neostriatum; Oxidopamine; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Stereotyped Behavior | 1993 |
Modifications in glutamatergic transmission after dopamine depletion of the nucleus accumbens. A combined in vivo/in vitro electrophysiological study in the rat.
Topics: Adrenergic Agents; Animals; Dopamine; Electrophysiology; Glutamic Acid; Iontophoresis; Male; Membrane Potentials; Neurons; Neurotransmitter Agents; Nucleus Accumbens; Oxidopamine; Rats; Rats, Wistar; Synaptic Transmission; Time Factors | 1996 |
A continuous striatal infusion of 6-hydroxydopamine produces a terminal axotomy and delayed behavioral effects.
Topics: Animals; Autoradiography; Axons; Behavior, Animal; Binding, Competitive; Biogenic Monoamines; Cell Line; Choline; Corpus Striatum; Denervation; gamma-Aminobutyric Acid; Glutamic Acid; Immunohistochemistry; Male; Mazindol; Oxidopamine; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 1996 |
Modulation of neurotransmitter release by cholecystokinin in the neostriatum and substantia nigra of the rat: regional and receptor specificity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aspartic Acid; Cholecystokinin; Dopamine; Dynorphins; Endorphins; gamma-Aminobutyric Acid; Glutamic Acid; Homovanillic Acid; Kinetics; Male; Neostriatum; Neurons; Neurotransmitter Agents; Organ Specificity; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Substantia Nigra; Time Factors | 1996 |
Dopamine-glutamate interactions in the striatum: behaviourally relevant modification of excitotoxicity by dopamine receptor-mediated mechanisms.
Topics: Analysis of Variance; Animals; Corpus Striatum; Dopamine; Functional Laterality; Glutamic Acid; Haloperidol; Male; Maze Learning; Motor Activity; Neurotoxins; Oxidopamine; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Dopamine D2; Substantia Nigra | 1996 |
Extracellular levels of glutamate and aspartate in the entopeduncular nucleus of the rat determined by microdialysis: regulation by striatal dopamine D2 receptors via the indirect striatal output pathway?
Topics: Animals; Aspartic Acid; Corpus Striatum; Dopamine Agonists; Dopamine Antagonists; Glutamic Acid; Hypothalamus; Male; Microdialysis; Neural Pathways; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Reserpine; Veratridine | 1997 |
Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion.
Topics: Animals; Corpus Striatum; Cytoplasm; Functional Laterality; Glutamic Acid; Kinetics; Male; Microdialysis; Microscopy, Immunoelectron; Mitochondria; Oxidopamine; Potassium; Prosencephalon; Rats; Rats, Sprague-Dawley; Synapses; Time Factors | 1999 |
Dopamine D1 receptor modulation of glutamate receptor messenger RNA levels in the neocortex and neostriatum of unilaterally 6-hydroxydopamine-lesioned rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Design; Gene Expression Regulation; Glutamic Acid; In Situ Hybridization; Male; Motor Activity; Neocortex; Nerve Tissue Proteins; Neurotoxins; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Metabotropic Glutamate; RNA, Messenger; Schizophrenia; Stereotyped Behavior; Sympatholytics; Tegmentum Mesencephali | 1999 |
Locomotor-activity-induced changes in striatal levels of preprotachykinin and preproenkephalin mRNA. Regulation by the dopaminergic and glutamatergic systems.
Topics: Animals; Apomorphine; Benzazepines; Corpus Striatum; Denervation; Dizocilpine Maleate; Dopamine; Dopamine Antagonists; Enkephalins; Excitatory Amino Acid Antagonists; Female; Gene Expression Regulation; Glutamic Acid; In Situ Hybridization; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Running; Tachykinins | 1999 |
Differential regulation of glutamate, aspartate and gamma-amino-butyrate release by N-methyl-D-aspartate receptors in rat striatum after partial and extensive lesions to the nigro-striatal dopamine pathway.
Topics: Animals; Aspartic Acid; Corpus Striatum; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Homeostasis; Kinetics; Male; Microdialysis; Oxidopamine; Prosencephalon; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 1999 |
Rat B(2) sequences are induced in the hippocampal CA1 region after transient global cerebral ischemia.
Topics: Amino Acid Sequence; Animals; Apoptosis; Base Sequence; Blotting, Northern; Cloning, Molecular; DNA; Gene Expression Regulation; Glutamic Acid; Hippocampus; Ischemic Attack, Transient; Molecular Sequence Data; Oxidopamine; Rats; Rats, Sprague-Dawley; Rats, Wistar | 1999 |
Nicotine stimulation of extracellular glutamate levels in the nucleus accumbens: neuropharmacological characterization.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acid Transport System X-AG; Animals; Aspartic Acid; ATP-Binding Cassette Transporters; Biological Transport; Denervation; Dicarboxylic Acids; Dopamine; Extracellular Space; Glutamic Acid; Haloperidol; Kainic Acid; Kinetics; Male; Mecamylamine; Microdialysis; Neurotransmitter Uptake Inhibitors; Nicotine; Nucleus Accumbens; Oxidopamine; Pyrrolidines; Rats; Rats, Sprague-Dawley | 2000 |
Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion.
Topics: Animals; Apomorphine; Denervation; Dopamine Agonists; Dopamine Antagonists; Glutamic Acid; Haloperidol; Immunohistochemistry; Male; Motor Cortex; Neostriatum; Nerve Degeneration; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Time Factors | 2000 |
Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Denervation; Dizocilpine Maleate; Functional Laterality; Glutamic Acid; Male; Microdialysis; Neurons; Oxidopamine; Parkinsonian Disorders; Perfusion; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2000 |
Regulation of tyrosine hydroxylase activity and phosphorylation at Ser(19) and Ser(40) via activation of glutamate NMDA receptors in rat striatum.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Antibody Specificity; Catalytic Domain; Caudate Nucleus; Colforsin; Dihydroxyphenylalanine; Enzyme Inhibitors; Excitatory Amino Acid Agonists; Glutamic Acid; In Vitro Techniques; Male; N-Methylaspartate; Neurons; Okadaic Acid; Oxidopamine; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Serine; Sympatholytics; Tyrosine 3-Monooxygenase | 2000 |
Fetal ventral mesencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum.
Topics: Animals; Apomorphine; Benzazepines; Brain Tissue Transplantation; Corpus Striatum; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Fetal Tissue Transplantation; Glutamic Acid; Membrane Potentials; Mesencephalon; Microdialysis; Microelectrodes; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase | 2000 |
Environmental modulation of the response to amphetamine: dissociation between changes in behavior and changes in dopamine and glutamate overflow in the rat striatal complex.
Topics: Amphetamine; Animals; Apomorphine; Aspartic Acid; Behavior, Animal; Central Nervous System Stimulants; Dopamine; Dopamine Agonists; Dopamine Uptake Inhibitors; Environment; Glutamic Acid; Male; Microdialysis; Neostriatum; Oxidopamine; Rats; Rats, Sprague-Dawley; Sympathectomy, Chemical; Sympatholytics | 2000 |
Role of corticostriatal and nigrostriatal inputs in malonate-induced striatal toxicity.
Topics: Adrenergic Agents; Afferent Pathways; Animals; Cell Count; Cerebral Cortex; Corpus Striatum; Dopamine; Glutamic Acid; Male; Malonates; Neurons; Oxidopamine; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2001 |
Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture.
Topics: 1-Methyl-4-phenylpyridinium; Adrenergic Agents; Animals; Cell Survival; Cells, Cultured; Dopamine; Glutamic Acid; Herbicides; Mesencephalon; Neurons; Oxidopamine; Rats; Reactive Oxygen Species; Receptors, Calcitriol; Vitamin D | 2001 |
Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions.
Topics: Amphetamine; Animals; Dizocilpine Maleate; Energy Metabolism; Excitatory Amino Acid Antagonists; Functional Laterality; Glutamic Acid; Male; Motor Activity; Neostriatum; Neural Pathways; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Subthalamic Nucleus; Succinate Dehydrogenase; Sympatholytics; Synaptic Transmission | 2001 |
Effect of microiontophoretic application of dopamine on subthalamic nucleus neuronal activity in normal rats and in rats with unilateral lesion of the nigrostriatal pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Apomorphine; Dopamine; Dopamine Agonists; Drug Interactions; gamma-Aminobutyric Acid; Glutamic Acid; Iontophoresis; Male; Neostriatum; Neural Pathways; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Dopamine D1; Substantia Nigra; Subthalamic Nucleus; Sympatholytics | 2001 |
Blockade of NMDA receptors by MK-801 reverses the changes in striatal glutamate immunolabeling in 6-OHDA-lesioned rats.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Glutamic Acid; Immunochemistry; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Synapses | 2001 |
Prevention of neurotoxin damage of 6-OHDA to dopaminergic nigral neuron by subthalamic nucleus lesions.
Topics: Afferent Pathways; Animals; Biomarkers; Dopamine; Excitatory Amino Acid Agonists; Glutamic Acid; Kainic Acid; Male; Medial Forebrain Bundle; Microinjections; Nerve Degeneration; Nerve Tissue Proteins; Neurons; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Subthalamic Nucleus; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2000 |
MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Sympatholytics; Synaptic Transmission | 2002 |
Intraplantar injection of glutamate evokes peripheral adenosine release in the rat hind paw: involvement of peripheral ionotropic glutamate receptors and capsaicin-sensitive sensory afferents.
Topics: Adenosine; Animals; Capsaicin; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Feedback, Physiological; Formaldehyde; Glutamic Acid; Hindlimb; Injections, Subcutaneous; Male; Microdialysis; Neurons, Afferent; Oxidopamine; Pain Measurement; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Skin | 2002 |
Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Drug Administration Schedule; Drug Antagonism; Extracellular Space; Glutamic Acid; Immunohistochemistry; Male; Microdialysis; Microscopy, Electron; Motor Activity; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Synapses | 2002 |
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.
Topics: Amidohydrolases; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dronabinol; Endocannabinoids; Enzyme Inhibitors; Glutamic Acid; Glycerides; Hydrolysis; In Vitro Techniques; Membrane Potentials; Neurons; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Synaptic Transmission | 2002 |
Effect of glutamatergic systems on in vivo binding of [(125)I]beta-CIT in the brain of a rat model of Parkinson's disease.
Topics: Animals; Autoradiography; Binding, Competitive; Cocaine; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Glutamic Acid; In Vitro Techniques; Iodine Radioisotopes; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Serotonin; Sympatholytics | 2002 |
Subthalamic GAD gene therapy in a Parkinson's disease rat model.
Topics: Animals; Dependovirus; Disease Models, Animal; Dopamine; Electric Stimulation; Electrophysiology; gamma-Aminobutyric Acid; Genetic Therapy; Genetic Vectors; Glutamate Decarboxylase; Glutamic Acid; Humans; Ibotenic Acid; Isoenzymes; Male; Mesencephalon; Mice; Motor Activity; Nerve Degeneration; Neurons; Oxidopamine; Parkinsonian Disorders; Phenotype; Rats; Stem Cells; Substantia Nigra; Subthalamic Nucleus; Synaptic Transmission; Transgenes | 2002 |
Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Glutamic Acid; Male; Microdialysis; N-Methylaspartate; Oxidopamine; Parkinsonian Disorders; Perfusion; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Wakefulness | 2002 |
Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats.
Topics: Animals; Corpus Striatum; Denervation; Dopamine; Glutamic Acid; Male; Microdialysis; Oxidopamine; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Time Factors; Triazoles | 2003 |
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Binding, Competitive; Cannabinoid Receptor Modulators; Cerebellum; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Endocannabinoids; Excitatory Postsynaptic Potentials; Fatty Acids, Unsaturated; Glutamic Acid; Glycerides; In Vitro Techniques; Levodopa; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Phospholipase D; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug | 2003 |
Group I mGluR ligands fail to affect 6-hydroxydopamine- induced death and glutamate release of PC12 cells.
Topics: Adrenergic Agents; Alanine; Animals; Apoptosis; Cell Survival; DNA Fragmentation; Drug Interactions; Glutamic Acid; Ligands; Methoxyhydroxyphenylglycol; Oxidopamine; PC12 Cells; Rats; Receptors, Metabotropic Glutamate | 2003 |
The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis.
Topics: Adrenergic Agents; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Aspartic Acid; Basal Ganglia; Chromatography, High Pressure Liquid; Excitatory Amino Acid Agonists; gamma-Aminobutyric Acid; Glutamic Acid; Immunohistochemistry; Injections, Intraventricular; Kainic Acid; Male; Microdialysis; Models, Animal; Oxidopamine; Parkinson Disease; Potassium; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2003 |
Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine-treated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations.
Topics: Animals; Apomorphine; Corpus Striatum; Glutamic Acid; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2004 |
L-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease.
Topics: Animals; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2004 |
[Relationship between neurotoxicity of 6-hydroxydopamine and glutamate transport].
Topics: Amino Acid Transport System X-AG; Animals; Apoptosis; Corpus Striatum; Glutamic Acid; Male; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Rats, Sprague-Dawley | 2003 |
Extracellular taurine in the substantia nigra: taurine-glutamate interaction.
Topics: Adrenergic Agents; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Aspartic Acid; Brain Chemistry; Calcium; Chelating Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Interactions; Egtazic Acid; Excitatory Amino Acid Antagonists; Extracellular Space; gamma-Aminobutyric Acid; Glutamic Acid; Kainic Acid; Ketamine; Male; Membrane Potentials; Microdialysis; N-Methylaspartate; Oxidopamine; Potassium; Rats; Rats, Sprague-Dawley; Substantia Nigra; Taurine; Time Factors; Zinc | 2004 |
Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine Agonists; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Models, Animal; Oxidopamine; Parkinson Disease; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine D2; Synaptic Transmission | 2004 |
Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Basal Ganglia; Denervation; Disease Models, Animal; Efferent Pathways; Extracellular Fluid; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Male; Models, Neurological; Neostriatum; Neurons; Oxidopamine; Parkinsonian Disorders; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Substantia Nigra | 2004 |
Cerebral glutamate metabolism in Parkinson's disease: an in vivo dynamic (13)C NMS study in the rat.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Carbon Isotopes; Disease Models, Animal; Dopamine; Glutamic Acid; Glutaminase; Glutamine; Infusions, Intravenous; Levodopa; Lipid Metabolism; Magnetic Resonance Spectroscopy; Male; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Sodium Acetate | 2005 |
Dopamine depletion alters responses to glutamate and GABA in the rat subthalamic nucleus.
Topics: Animals; Dopamine; GABA Agonists; Glutamic Acid; In Vitro Techniques; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, GABA; Receptors, Glutamate; Subthalamic Nucleus | 2005 |
Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine.
Topics: Adrenergic Agents; Animals; Benzazepines; Bicuculline; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; GABA Antagonists; Glutamic Acid; Magnesium; Male; N-Methylaspartate; Neurons; Oxidopamine; Piperidines; Potassium Chloride; Quinuclidines; Raclopride; Rats; Rats, Sprague-Dawley; Substance P; Substantia Nigra; Tetrodotoxin; Time Factors | 2005 |
8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Aspartic Acid; Corpus Striatum; Denervation; Disease Models, Animal; Glutamic Acid; Injections, Subcutaneous; Male; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Receptor Agonists; Sympatholytics | 2005 |
Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Denervation; Glutamic Acid; Levodopa; Male; Movement Disorders; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Subthalamic Nucleus; Sympatholytics; Synaptic Transmission | 2005 |
Mesocortical dopamine neurons operate in distinct temporal domains using multimodal signaling.
Topics: Action Potentials; Animals; Benzazepines; Bicuculline; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Radiation; Electric Stimulation; Electrochemistry; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; GABA Antagonists; Glutamic Acid; Immunohistochemistry; Male; Medial Forebrain Bundle; Neurons; Oxidopamine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Signal Transduction; Sulpiride; Synaptic Transmission; Tetrodotoxin; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2005 |
Pallidal origin of GABA release within the substantia nigra pars reticulata during high-frequency stimulation of the subthalamic nucleus.
Topics: Animals; Cell Count; Chromatography, High Pressure Liquid; Dose-Response Relationship, Radiation; Electric Stimulation; Electrochemistry; Electrodes; Functional Laterality; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Immunohistochemistry; Male; Microdialysis; Oxidopamine; Rats; Rats, Sprague-Dawley; Substantia Nigra; Subthalamic Nucleus; Tyrosine 3-Monooxygenase | 2005 |
Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Animals, Newborn; Brain; Cell Death; Cell Nucleus; Cerebral Cortex; Corpus Striatum; Dopamine; Drug Synergism; Glutamic Acid; N-Methylaspartate; Nerve Degeneration; Neurons; Neurotoxins; Organ Culture Techniques; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; Disease Models, Animal; Disease Progression; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electrochemistry; Encephalomyelitis, Autoimmune, Experimental; Endocannabinoids; Exploratory Behavior; Furans; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamic Acid; Huntington Disease; Male; Malonates; Movement Disorders; Multiple Sclerosis; Nitro Compounds; Oxidopamine; Polyunsaturated Alkamides; Propionates; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase | 2006 |
Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; Glutamic Acid; Male; Microdialysis; Oxidopamine; Propylamines; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2006 |
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Autoradiography; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electrochemistry; gamma-Aminobutyric Acid; Gene Expression; Glutamic Acid; In Situ Hybridization; Injections, Intraventricular; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Rotarod Performance Test; Superoxide Dismutase; Superoxide Dismutase-1; Tyrosine 3-Monooxygenase | 2006 |
Field potential recording in the ventral tegmental area: pharmacological and toxicological evaluations of postsynaptic dopaminergic neuron activity.
Topics: Action Potentials; Animals; Animals, Newborn; Dopamine; Excitatory Amino Acid Antagonists; GABA Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Neural Pathways; Neurons; Organ Culture Techniques; Oxidopamine; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Sympatholytics; Synapses; Synaptic Transmission; Ventral Tegmental Area | 2006 |
Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Models, Animal; Glutamic Acid; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin Receptor Agonists | 2007 |
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Bicuculline; Drug Synergism; Drug Therapy, Combination; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Injections; Levodopa; Male; Microdialysis; Motor Activity; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Perfusion; Piperidines; Postural Balance; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Sodium Channel Blockers; Stereotaxic Techniques; Substantia Nigra; Tetrodotoxin; Thalamus | 2007 |
Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Topics: Animals; Benzoates; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Glycine; Male; Molecular Structure; Nerve Degeneration; Neural Pathways; Neuroprotective Agents; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Substantia Nigra; Treatment Outcome; Tyrosine 3-Monooxygenase | 2007 |
NMDA-mediated release of glutamate and GABA in the subthalamic nucleus is mediated by dopamine: an in vivo microdialysis study in rats.
Topics: Animals; Dopamine; Dopamine Antagonists; Drug Interactions; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Extracellular Fluid; gamma-Aminobutyric Acid; Glutamic Acid; Male; Microdialysis; N-Methylaspartate; Neurons; Neurotoxins; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine; Subthalamic Nucleus; Synaptic Transmission | 2007 |
Neuroprotection and free radical scavenging effects of Osmanthus fragrans.
Topics: Animals; Arachidonic Acid; Female; Ferrous Compounds; Free Radical Scavengers; Glutamic Acid; Lipid Peroxidation; Neurons; Neuroprotective Agents; Oleaceae; Oxidopamine; Plant Extracts; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar | 2007 |
Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats.
Topics: Animals; Corpus Striatum; Dose-Response Relationship, Drug; Drug Resistance; Extracellular Fluid; Glutamic Acid; Male; Microdialysis; Neural Inhibition; Oxidopamine; Parkinsonian Disorders; Piperidines; Presynaptic Terminals; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Sympatholytics; Synaptic Transmission; Up-Regulation | 2008 |
GABAergic mechanism mediated via D receptors in the rat periaqueductal gray participates in the micturition reflex: an in vivo microdialysis study.
Topics: Animals; Benzazepines; Denervation; Disease Models, Animal; Dopamine; Dopamine Antagonists; Extracellular Space; gamma-Aminobutyric Acid; Glutamic Acid; Male; Microdialysis; Oxidopamine; Parkinson Disease; Periaqueductal Gray; Rats; Rats, Wistar; Receptors, Dopamine D1; Reflex; Sympatholytics; Urination | 2008 |
Apomorphine-induced differences in cortical and striatal EEG and their glutamatergic mediation in 6-hydroxydopamine-treated rats.
Topics: Alpha Rhythm; Animals; Apomorphine; Behavior, Animal; Beta Rhythm; Cerebral Cortex; Corpus Striatum; Delta Rhythm; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agonists; Drug Interactions; Electroencephalography; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Osmotic Fragility; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Sympatholytics; Theta Rhythm | 2008 |
Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Dopamine; Glutamic Acid; Male; Mesencephalon; Nerve Degeneration; Neural Pathways; Neuronal Plasticity; Neurons; Nucleus Accumbens; Oxidopamine; Parkinsonian Disorders; Phenotype; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase; Ventral Tegmental Area; Vesicular Glutamate Transport Protein 2 | 2008 |
Dopaminergic but not glutamatergic neurotransmission is increased in the striatum after selective cyclooxygenase-2 inhibition in normal and hemiparkinsonian rats.
Topics: Animals; Celecoxib; Corpus Striatum; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glutamic Acid; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Pyrazoles; Rats; Rats, Wistar; Substantia Nigra; Sulfonamides; Synaptic Transmission | 2008 |
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Motor Activity; Narcotic Antagonists; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Substantia Nigra; Thalamus; Time Factors | 2008 |
Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzamides; Bicuculline; Bridged Bicyclo Compounds, Heterocyclic; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; GABA Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Hindlimb Suspension; Male; Microdialysis; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Substantia Nigra; Thiophenes; Time Factors | 2008 |
NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
Topics: Analysis of Variance; Animals; Aspartic Acid; Brain-Derived Neurotrophic Factor; Cell Count; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Functional Laterality; Glutamic Acid; Male; Microdialysis; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation | 2009 |
Effects of subthalamic nucleus lesions and stimulation upon glutamate levels in the dopamine-depleted rat striatum.
Topics: Animals; Corpus Striatum; Dopamine; Down-Regulation; Electric Stimulation; Glutamic Acid; Male; Neural Inhibition; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus; Sympatholytics; Synaptic Transmission; Up-Regulation | 2009 |
Optical imaging of rat prefrontal neuronal activity evoked by stimulation of the ventral tegmental area.
Topics: Action Potentials; Animals; Brain Mapping; Denervation; Dopamine; Electric Stimulation; Electrophysiology; Fluorescent Dyes; Glutamic Acid; Microscopy, Fluorescence; Neural Inhibition; Neural Pathways; Neurons; Neurotoxins; Optics and Photonics; Oxidopamine; Prefrontal Cortex; Rats; Rats, Wistar; Staining and Labeling; Synaptic Transmission; Ventral Tegmental Area | 2009 |
Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Electrophysiology; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; GABA Agonists; gamma-Aminobutyric Acid; Glutamic Acid; Male; Movement; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Patch-Clamp Techniques; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; Sympatholytics; Synaptic Transmission; Tetrodotoxin | 2009 |
The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway.
Topics: Amino Acids; Animals; Antiparkinson Agents; Benzimidazoles; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Neural Pathways; Oligopeptides; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Substantia Nigra; Thalamus | 2009 |
The dual dopamine-glutamate phenotype of growing mesencephalic neurons regresses in mature rat brain.
Topics: Adrenergic Agents; Aging; Animals; Axons; Cell Count; Dopamine; Glutamic Acid; Mesencephalon; Neurons; Oxidopamine; Rats; RNA, Messenger; Synapses; Tyrosine 3-Monooxygenase; Vesicular Glutamate Transport Protein 2 | 2009 |
Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cerebral Cortex; Corpus Striatum; Dendrites; Disease Models, Animal; Dopamine; Excitatory Amino Acid Agents; Fluoresceins; Glutamic Acid; Male; Neurons; Organ Culture Techniques; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Silver Staining | 2010 |
Action of 6-amino-3-pyridinols as novel antioxidants against free radicals and oxidative stress in solution, plasma, and cultured cells.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Tocopherol; Animals; Antioxidants; Cytoprotection; Fatty Acids, Unsaturated; Free Radical Scavengers; Glutamic Acid; Lipid Peroxidation; Oxidation-Reduction; Oxidative Stress; Oxidopamine; PC12 Cells; Pyridones; Rats | 2010 |
Pre-synaptic glutamate-induced activation of DA release in the striatum after partial nigral lesion.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids; Animals; Brain Injuries; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dopamine Agents; Electrochemotherapy; Glutamic Acid; Homovanillic Acid; Male; Microdialysis; Oxidopamine; Presynaptic Terminals; Rats; Rats, Wistar; Substantia Nigra | 2010 |
Effects of zona incerta lesions on striatal neurochemistry and behavioral asymmetry in 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Behavioral Symptoms; Corpus Striatum; Disease Models, Animal; Dopamine; Glutamic Acid; Male; Microdialysis; Motor Activity; Neurochemistry; Neurotoxicity Syndromes; Oxidopamine; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Subthalamus; Tyrosine 3-Monooxygenase | 2010 |
Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Cytoprotection; Disease Models, Animal; Glutamic Acid; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinsonian Disorders; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate | 2010 |
Dopaminergic neurons of system x(c)⁻-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity.
Topics: Aging; Amino Acid Transport System y+; Animals; Corpus Striatum; Cystine; Dopamine; Glioma; Glutamic Acid; Glutathione; Mice; Mice, Knockout; Neurodegenerative Diseases; Neurons; Oxidopamine; Substantia Nigra; Tumor Cells, Cultured | 2011 |
Enhanced glutamate, IP3 and cAMP activity in the cerebral cortex of unilateral 6-hydroxydopamine induced Parkinson's rats: effect of 5-HT, GABA and bone marrow cell supplementation.
Topics: Animals; Behavior, Animal; Bone Marrow Cells; Bone Marrow Transplantation; Cerebral Cortex; Cyclic AMP; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamic Acid; Inositol Phosphates; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Serotonin; Substantia Nigra; Transplantation, Homologous | 2011 |
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
Topics: Animals; Antioxidants; Cannabinoids; Cyclohexanols; Disease Models, Animal; Dopamine; Dronabinol; Glutamic Acid; Lipopolysaccharides; Male; Mice; Motor Activity; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Substantia Nigra; Tyrosine 3-Monooxygenase | 2011 |
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Benzazepines; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Male; Microdialysis; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists | 2011 |
The glutamatergic component of the mesocortical pathway emanating from different subregions of the ventral midbrain.
Topics: Adrenergic Agents; Animals; Biotin; Dextrans; Excitatory Amino Acid Agonists; Glutamate Decarboxylase; Glutamic Acid; Ibotenic Acid; Male; Nerve Fibers; Neural Pathways; Neurons; Oxidopamine; Phytohemagglutinins; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase; Ventral Tegmental Area; Vesicular Glutamate Transport Protein 2 | 2012 |
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses.
Topics: Animals; Anti-Inflammatory Agents; Anxiety; Apoptosis; Autoradiography; Cell Survival; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Glutamic Acid; Immunohistochemistry; L-Lactate Dehydrogenase; Male; Matrix Metalloproteinase 9; Nerve Degeneration; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Simvastatin; Substantia Nigra; Tritium; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2011 |
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; Dopamine; Glutamic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Triazines; Triazoles | 2012 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Levodopa; Male; Monoamine Oxidase; Motor Neuron Disease; Oxidopamine; Parkinson Disease; Picolinic Acids; Protein Binding; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate; Substantia Nigra; Thallium; Transfection; Triazoles; Tyrosine 3-Monooxygenase | 2012 |
Frequency selectivity and dopamine-dependence of plasticity at glutamatergic synapses in the subthalamic nucleus.
Topics: Animals; Dopamine; Electric Stimulation; Excitatory Postsynaptic Potentials; Glutamic Acid; Male; Neuronal Plasticity; Neurons; Organ Culture Techniques; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Subthalamic Nucleus; Synapses; Synaptic Transmission | 2012 |
Striatal NTS1 , dopamine D2 and NMDA receptor regulation of pallidal GABA and glutamate release--a dual-probe microdialysis study in the intranigral 6-hydroxydopamine unilaterally lesioned rat.
Topics: Adrenergic Agents; Animals; Corpus Striatum; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Male; Microdialysis; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotensin; Synaptic Transmission | 2012 |
Metabolic changes detected by ex vivo high resolution 1H NMR spectroscopy in the striatum of 6-OHDA-induced Parkinson's rat.
Topics: Animals; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Magnetic Resonance Spectroscopy; Male; Multivariate Analysis; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2013 |
Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Autoradiography; Behavior, Animal; Dyskinesia, Drug-Induced; Electrophysiological Phenomena; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Microinjections; Nociceptin; Opioid Peptides; Oxidopamine; Postural Balance; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2012 |
Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.
Topics: Animals; Brain; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dopaminergic Neurons; Enzyme Inhibitors; Glutamic Acid; Glycogen Synthase Kinase 3; Humans; Mice; Microglia; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats | 2013 |
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Phenols; Piperidines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2013 |
Parkinson's disease: in vivo metabolic changes in the frontal and parietal cortices in 6-OHDA treated rats during different periods.
Topics: Animals; Aspartic Acid; Choline; Corpus Striatum; Creatine; Disease Models, Animal; Frontal Lobe; Functional Laterality; Functional Neuroimaging; Glutamates; Glutamic Acid; Glutamine; Magnetic Resonance Spectroscopy; Male; Motor Activity; Oxidopamine; Parietal Lobe; Parkinson Disease, Secondary; Rats; Substantia Nigra; Time Factors | 2014 |
Neuroprotective effects of dipeptide analogue of brain-derived neurotrophic factor GSB-106 in in vitro experiments.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Survival; Cells, Cultured; Dipeptides; Dose-Response Relationship, Drug; Glutamic Acid; Hippocampus; Humans; Hydrogen Peroxide; Mice; Neurons; Neuroprotective Agents; Oxidopamine; Spectrophotometry | 2013 |
Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model.
Topics: Animals; Ceftriaxone; Corpus Striatum; Glutamic Acid; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2014 |
Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of L-dopa by normalizing Parkinson's disease-induced neurochemical imbalance.
Topics: Acupuncture Therapy; Animals; Antiparkinson Agents; Brain Chemistry; Combined Modality Therapy; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Movement; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Substantia Nigra | 2014 |
GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: implication for Parkinson's disease.
Topics: Acetylcholine; Action Potentials; Animals; Corpus Striatum; Depression, Chemical; Dopamine; Glutamic Acid; Interneurons; Male; Mice; Mice, Inbred C57BL; Models, Neurological; Muscarinic Agonists; Muscarinic Antagonists; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Receptors, N-Methyl-D-Aspartate; Secretory Rate; Synaptic Transmission | 2014 |
Simvastatin prevents neuroinflammation by inhibiting N-methyl-D-aspartic acid receptor 1 in 6-hydroxydopamine-treated PC12 cells.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Dose-Response Relationship, Drug; Glutamic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Oxidopamine; PC12 Cells; Rats; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Simvastatin; Sympatholytics; Time Factors | 2014 |
[Studying in vitro neuroprotective properties of GK-2(h)--a new original mimetic of human nerve growth factor].
Topics: Animals; Cell Line; Dipeptides; Glutamic Acid; Hippocampus; Humans; Hydrogen Peroxide; Mice; Molecular Mimicry; Nerve Growth Factor; Neurons; Neuroprotective Agents; Oxidopamine; PC12 Cells; Rats | 2014 |
NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Extracellular Space; Functional Laterality; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus | 2014 |
Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action.
Topics: Amino Acid Transport System X-AG; Anilides; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Corpus Striatum; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dopamine Antagonists; Excitatory Amino Acid Agents; Globus Pallidus; Glutamic Acid; Haloperidol; Male; Oxidopamine; Parkinsonian Disorders; Rats, Wistar; Receptors, Metabotropic Glutamate; Synapses; Synaptic Transmission; Tissue Culture Techniques | 2014 |
The possible mechanism of Parkinson's disease progressive damage and the preventive effect of GM1 in the rat model induced by 6-hydroxydopamine.
Topics: Animals; bcl-2-Associated X Protein; Brain; Calcium; Calmodulin; Disease Progression; G(M1) Ganglioside; Glutamic Acid; Infusions, Parenteral; Male; Malondialdehyde; Mitochondria; Neuroprotective Agents; Nitric Oxide Synthase Type I; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Trace Elements | 2014 |
[Neuroprotective effect of neuroglutam under conditions of activated free radical oxidation].
Topics: Animals; Brain Ischemia; Cell Line, Tumor; Erythrocytes; Free Radicals; Glutamic Acid; Hemolysis; Humans; Male; Neurons; Neuroprotective Agents; Oxidation-Reduction; Oxidative Stress; Oxidopamine; Rats; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2014 |
Effects of endogenous melatonin on glutamate and GABA rhythms in the striatum of unilateral 6-hydroxydopamine-lesioned rats.
Topics: Animals; Chromatography, Liquid; Circadian Rhythm; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Male; Melatonin; Oxidopamine; Rats; Rats, Sprague-Dawley | 2015 |
Disruption of dopaminergic transmission remodels tripartite synapse morphology and astrocytic calcium activity within substantia nigra pars reticulata.
Topics: Animals; Astrocytes; Benzazepines; Calcium; Calcium Signaling; Dopamine; Glutamic Acid; Male; Oxidopamine; Pars Reticulata; Rats; Sulpiride; Synapses; Synaptic Transmission | 2015 |
Alterations in the motor cortical and striatal glutamatergic system and D-serine levels in the bilateral 6-hydroxydopamine rat model for Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Glutamic Acid; Male; Motor Cortex; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Serine | 2015 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Glutamic Acid; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Oxidopamine; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors | 2015 |
Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
Topics: Adrenergic Agents; Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Glutamic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligodeoxyribonucleotides, Antisense; Oxidopamine; Parkinsonian Disorders; Radiopharmaceuticals; Receptors, G-Protein-Coupled; Stereotyped Behavior; Synaptic Transmission; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
Contra-directional Coupling of Nur77 and Nurr1 in Neurodegeneration: A Novel Mechanism for Memantine-Induced Anti-inflammation and Anti-mitochondrial Impairment.
Topics: Animals; Cell Survival; Cytochromes c; Dopamine Plasma Membrane Transport Proteins; Gene Knockdown Techniques; Glutamic Acid; Inflammation; Interleukin-6; L-Lactate Dehydrogenase; MAP Kinase Signaling System; Memantine; Mitochondria; Nerve Degeneration; Neuroprotection; Nuclear Receptor Subfamily 4, Group A, Member 1; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; PC12 Cells; Rats; Subcellular Fractions; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2016 |
Metabolic, synaptic and behavioral impact of 5-week chronic deep brain stimulation in hemiparkinsonian rats.
Topics: Animals; Basal Ganglia; Behavior, Animal; Corpus Striatum; Deep Brain Stimulation; Dopamine; Glutamic Acid; Neuronal Plasticity; Oxidopamine; Parkinson Disease; Rats; Substantia Nigra; Subthalamic Nucleus; Time | 2016 |
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists | 2016 |
Stimulus-dependent neuronal cell responses in SH-SY5Y neuroblastoma cells.
Topics: Apoptosis; Calcium; Cell Line, Tumor; Cell Survival; Glucose Oxidase; Glutamic Acid; Humans; Ions; Membrane Potential, Mitochondrial; Neuroblastoma; Neurons; Oxidopamine; Receptor-Interacting Protein Serine-Threonine Kinases; Up-Regulation | 2016 |
Impact of partial dopamine depletion on cognitive flexibility in BDNF heterozygous mice.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cognition; Conditioning, Operant; Corpus Striatum; Dopamine; Glutamic Acid; Heterozygote; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neostriatum; Oxidopamine; Reversal Learning | 2016 |
L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum.
Topics: Amino Acids; Animals; Aspartic Acid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Forelimb; gamma-Aminobutyric Acid; Glutamic Acid; Glycine; Levodopa; Mice; Oxidopamine; Rotarod Performance Test; Taurine; Tyrosine | 2016 |
Modulation of Corpus Striatal Neurochemistry by Astrocytes and Vasoactive Intestinal Peptide (VIP) in Parkinsonian Rats.
Topics: Animals; Astrocytes; Corpus Striatum; gamma-Aminobutyric Acid; Glial Fibrillary Acidic Protein; Gliosis; Glutamate Decarboxylase; Glutamic Acid; Glutathione; Lactic Acid; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Vasoactive Intestinal Peptide | 2016 |
The Role of Group II Metabotropic Glutamate Receptors in the Striatum in Electroacupuncture Treatment of Parkinsonian Rats.
Topics: Analysis of Variance; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Electroacupuncture; Excitatory Amino Acid Agents; Gene Expression Regulation; Glutamic Acid; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; RNA, Messenger; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2017 |
Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Catalepsy; Disease Models, Animal; Dopamine Agonists; Forelimb; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Transfection | 2016 |
Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Line; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glutamic Acid; Hippocampus; Humans; Mice; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Peptides, Cyclic; Piracetam | 2016 |
The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Agents; GABA Agents; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Motor Cortex; Movement; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Signal Transduction; Sympatholytics; Tardive Dyskinesia | 2016 |
Metabotropic glutamate receptor 5 mediates the suppressive effect of 6-OHDA-induced model of Parkinson's disease on liver cancer.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Glutamic Acid; Liver; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5 | 2017 |
Investigation of the neuroprotective effects of a novel synthetic compound via the mitochondrial pathway.
Topics: Animals; bcl-X Protein; Calcium; Cell Differentiation; Cell Nucleus Shape; Cell Survival; Glutamic Acid; Membrane Potential, Mitochondrial; Mitochondria; Neuroprotective Agents; Neurotoxins; Oxidopamine; PC12 Cells; Rats; Reactive Oxygen Species; Signal Transduction | 2017 |
Microglia may compensate for dopaminergic neuron loss in experimental Parkinsonism through selective elimination of glutamatergic synapses from the subthalamic nucleus.
Topics: Animals; Animals, Newborn; Cells, Cultured; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Exploratory Behavior; Glutamic Acid; Male; Microglia; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phagocytosis; Prosencephalon; Rats; Rats, Wistar; Subthalamic Nucleus; Sympatholytics; Synapses | 2017 |
Activation and blockade of basolateral amygdala 5-HT
Topics: Animals; Anti-Anxiety Agents; Anxiety; Basolateral Nuclear Complex; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Male; Methylamines; Neural Pathways; Neurons; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyridines; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin Agents; Substantia Nigra; Sulfonamides | 2018 |
Effects of exercise on mGluR-mediated glutamatergic transmission in the striatum of hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Exercise Therapy; Glutamic Acid; Locomotion; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate | 2019 |
Wnt1 Promotes EAAT2 Expression and Mediates the Protective Effects of Astrocytes on Dopaminergic Cells in Parkinson's Disease.
Topics: Apoptosis; Astrocytes; beta Catenin; Cell Line; Coculture Techniques; Dopaminergic Neurons; Excitatory Amino Acid Transporter 2; Glutamic Acid; Humans; Oxidopamine; Parkinson Disease; Wnt Signaling Pathway; Wnt1 Protein | 2019 |
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; GABAergic Neurons; Glutamic Acid; Levodopa; Locomotion; Male; Medial Forebrain Bundle; Mice; Mice, Knockout; Movement; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Receptors, G-Protein-Coupled; RNA, Messenger; Serotonin; Tacrine; Tremor | 2020 |
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2020 |
Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Dose-Response Relationship, Drug; Excitatory Postsynaptic Potentials; Glutamic Acid; Levodopa; Male; Nerve Net; Organ Culture Techniques; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2020 |
Acute and Chronic Dopaminergic Depletion Differently Affect Motor Thalamic Function.
Topics: Adrenergic Agents; Animals; Basal Ganglia; Cerebral Cortex; Deep Brain Stimulation; Dopamine; Dopamine Agents; gamma-Aminobutyric Acid; Glutamic Acid; Immunohistochemistry; Levodopa; Male; Medial Forebrain Bundle; Microdialysis; Neurons; Oxidopamine; Rats; Rats, Sprague-Dawley; Tetrodotoxin; Thalamus | 2020 |
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
Topics: Allosteric Regulation; Animals; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Muscarinic Antagonists; Neostriatum; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Substantia Nigra; Sympatholytics | 2020 |
Downregulation of astroglial glutamate transporter GLT-1 in the lateral habenula is associated with depressive-like behaviors in a rat model of Parkinson's disease.
Topics: Animals; Astrocytes; Depression; Disease Models, Animal; Down-Regulation; Excitatory Amino Acid Transporter 2; Glutamic Acid; Habenula; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Rats; Substantia Nigra; Thalamus; Ventral Tegmental Area | 2021 |
Optogenetic stimulation of glutamatergic neurons in the cuneiform nucleus controls locomotion in a mouse model of Parkinson's disease.
Topics: Animals; Biomechanical Phenomena; Corpus Striatum; Disease Models, Animal; Glutamic Acid; Light; Locomotion; Mice; Mice, Transgenic; Midbrain Reticular Formation; Neurons; Optogenetics; Oxidopamine; Parkinson Disease; Rhodopsin | 2021 |
The modulatory effect of 100 Hz electroacupuncture on striatal synaptic plasticity in unilateral lesioned 6-OHDA rats.
Topics: Animals; Corpus Striatum; Electroacupuncture; Glutamic Acid; Humans; Long-Term Potentiation; Oxidopamine; Parkinson Disease; Rats | 2022 |
Chronic H
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Oxidopamine; Rats; RNA, Messenger | 2023 |
In Search of a Feedback Signal for Closed-Loop Deep Brain Stimulation: Stimulation of the Subthalamic Nucleus Reveals Altered Glutamate Dynamics in the Globus Pallidus in Anesthetized, 6-Hydroxydopamine-Treated Rats.
Topics: Animals; Deep Brain Stimulation; Feedback; Globus Pallidus; Glutamic Acid; Oxidopamine; Parkinson Disease; Rats; Subthalamic Nucleus | 2023 |